ABOS vs TECH · $73.3M cap vs P/E 65, rev $1.22B
Acumen Pharmaceuticals Inc (ABOS) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Acumen Pharmaceuticals Inc (ABOS) is a biotechnology company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
ABOS does not have a complete income-statement cache yet.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
ABOS currently screens at market cap $73.3M. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the ABOS and TECH stock pages for the full models.
Not investment advice.